Recurrent ovarian cancer: Is there a role for re-treatment with bevacizumab after an initial complete response to a bevacizumab-containing regimen?

BACKGROUND: Bevacizumab (Bev) has gained acceptance as an active agent in the treatment of epithelial ovarian cancer (EOC). Data is lacking on survival outcomes in patients who are re-treated with Bev after achieving a complete response to a Bev-containing regimen (BCR). Our primary objective was to...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: McCann, Georgia A., Smith, Blair, Backes, Floor J., Rath, Kellie, Chacko, Simi, Salani, Ritu, Eisenhauer, Eric, Fowler, Jeffrey, Cohn, David, Copeland, Larry, O’Malley, David
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3886294/
https://ncbi.nlm.nih.gov/pubmed/22885866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2012.08.001
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares